Recent progress in drug treatment for acute ischemic stroke

Cerebrovascular Diseases

Volumn 11, Issue SUPPL. 1, 2001, Pages 71-79

  Devuyst, G ^a   Bogousslavsky, J ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Abciximab; Antithrombotic drugs; Drug treatment for acute stroke; Neuroprotective drugs; Thrombolysis

Indexed keywords

ABCIXIMAB; ALTEPLASE; ANCROD; ANTICOAGULANT AGENT; BASIC FIBROBLAST GROWTH FACTOR; CITICOLINE; CLOMETHIAZOLE; EBSELEN; ELIPRODIL; FIBRINOGEN RECEPTOR ANTAGONIST; GAVESTINEL; GLYCINE; HEPARIN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LUBELUZOLE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NIMODIPINE; PIRACETAM; PROUROKINASE; STREPTOKINASE; TIRILAZAD;

BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEVER; FIBRINOLYTIC THERAPY; HUMAN; HYPOTHERMIA; INFECTION; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; NEUROPROTECTION; PRIORITY JOURNAL; QT INTERVAL; RISK BENEFIT ANALYSIS;

EID: 0035103427     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049128     Document Type: Conference Paper

References (58)

1. Tissue plasminogen activator for acute ischemic stroke
2. Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association
3. Thrombolytic therapy for acute ischemic stroke: Summary statement
4. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II)
5. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke
6. Alteplase not yet proven for acute ischaemic stroke
7. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke
8. Dichotomized efficacy end points and global endpoint analysis applied to the ECASS intention-to-treat data set: Post hoc analysis of ECASS I
9. A systems approach to immediate evaluation and management of hyperacute stroke: Experience at eight centers and implications for community practice and patient care
10. Thrombolytic therapy with streptokinase in acute ischemic stroke
11. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke
12. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group
13. Thrombolytic therapy versus control in acute ischemic stroke
14. Evolving toward effective therapy for acute ischemic stroke
15. Thrombolysis in acute stroke
16. Medical therapy for acute ischemic stroke
17. Meta-analysis of oral nimodipine trials in acute ischemic stroke
18. Intravenous Nimedipine West European Stroke Trial of nimodipine in the treatment of acute ischemic stroke
19. Termination of acute stroke studies involving Selfotel treatment
20. Cerestat (aptiganel hydrochloride) in the treatment of acute ischemic stroke: Results of phase 2 trial
21. Safety, tolerability and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke
22. Safety, tolerability and pharmacokinetics of the N-methyl-D-aspartate antagonist Ro-01-6794/706 in patients with acute ischemic stroke
23. Cerestat and other NMDA antagonists in ischemic stroke
24. Does neuroprotection improve stroke outcome?
25. Lubeluzole treatment of acute ischemic stroke
26. Acute ischemic stroke therapy. A clinical overview
27. Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke
28. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS)
29. High-dose tirilazad for acute stroke (RANTASS II)
30. Ebselen in acute ischemic stroke: A placebo-controlled, double-blind clinical trial
31. Clomethiazole Acute Stroke Study (CLASS)
32. The Clomethiazole Acute Stroke Study (CLASS): Results in 94 hemorrhagic stroke patients
33. Further evolution toward effective therapy for acute ischemic stroke
34. The Enlimomab Acute Stroke Trial: Final results
35. Treatment of acute ischemic stroke with piracetam
36. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline
37. A randomized dose-response trial of citicoline in acute ischemic stroke patients
38. BRAINS, a Phase II study of the neuroprotectant BAY x3702 in patients with ischemic stroke
39. Images: Intravenous magnesium efficacy in stroke trial
40. A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke
41. Brain temperature monitoring and modulation in patients with severe MCA infarction
42. The prognostic significance of subfebrility and fever in ischemic cerebral infarction
43. Mortality and morbidity of acute cerebral infarction related to temperature and basal analytic parameters
44. Fever in acute stroke worsens prognosis: A prospective study
45. Combating hyperthermia in acute stroke. A significant clinical concern
46. Moderate hypothermia in the treatment of patients with severe middle cerebral artery infarction
47. Fighting heart disease and stroke. Recommendations of the AHA stroke positioning task force
48. Stroke treatment: Promising but still struggling
49. Duration of neuroprotective treatment for ischemic stroke
50. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: A randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke
51. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism
52. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial
53. Intravenous tissue-type plasminogen activator for treatment of acute stroke. The standard treatment with alteplase to reverse stroke (STARS) study
54. Use of tissue-type plasminogen activator for acute ischemic stroke. The Cleveland area experience
55. Abciximab in acute ischemic stroke: A randomized, double-blind, placebo-controlled, dose-escalation study
56. Neuroprotective effects of glycine for therapy of acute ischaemic stroke
57. Phase II studies of the Glycine Antagonist GV150526 in acute stroke. The North American Experience
58. Ancrod in the treatment of acute ischemic stroke